Table 3 Health economic analysis
Mean | 95 % CI for mean | Median | SD | |
|---|---|---|---|---|
Arm A: Bevacizumab + paclitaxel (N = 66) | ||||
TTS, months | 7.3 | 6.3–8.2 | 5.9 | 4.0 |
Utility | 0.8 | 0.7–0.8 | 0.8 | 0.2 |
QALM | 5.9 | 5.0–6.8 | 5.1 | 3.7 |
Total incurred costs, CHF | 69,474 | 60,624–78,324 | 61,815 | 36,001 |
Costs per month, CHF | 10,044 | 9,216–10,871 | 9,385 | 3,367 |
Costs per QALM | 14,389 | 11,955–16,823 | 11,249 | 9,900 |
Arm B: Bevacizumab + capecitabine + cyclophosphamide (N = 63) | ||||
TTS, months | 8.5 | 6.7–10.2 | 6.8 | 7.0 |
Utility | 0.7 | 0.7–0.8 | 0.7 | 0.2 |
QALM | 6.5 | 5.0–8.1 | 5.0 | 6.3 |
Total incurred costs, CHF | 80,324 | 62,975–97,672 | 61,751 | 68,885 |
Costs per month, CHF | 10,229 | 9,317–11,142 | 9,158 | 3,622 |
Costs per QALM | 40,826 | −7,257–88,909 | 12,025 | 190,922 |